The pharmacodynamics and efficacy of Implanon®1

An overview of the data
  • H.B Croxatto
    Name and address for correspondence: Prof. H. Croxatto, Instituto Chileno de Medicina Reproductiva, Consultorio de Planificación Familiar, José Victorino Lastarria 29, Departamento 101, Santiago, Chile
    Instituto Chileno de Medicina Reproductiva, Santiago, Chile
    Search for articles by this author
  • L Mäkäräinen
    Department of Obstetrics and Gynecology, University of Oulu, Oulu,, Finland
    Search for articles by this author


      Implanon® is a long-acting reversible contraceptive method, consisting of a single rod that is applied subdermally. Ovulation inhibition was determined by serum progesterone (P) levels and ultrasound scanning (USS) of the ovaries. Ovarian function was further assessed by serum estradiol (E2) levels. The effects of Implanon on serum gonadotropin levels (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) and on cervical mucus were also investigated, by means of Insler scores and sperm penetration tests. The effect on the endometrium was assessed by endometrial biopsies and USS. The Pearl index was calculated over 13 studies performed according to Good Clinical Practice (GCP), including 1716 women using Implanon. Return of ovulation after implant removal was determined by P levels and USS of the ovaries.
      The contraceptive efficacy of Implanon was high, with zero pregnancies during 53,530 cycles (4103 woman-years), resulting in a Pearl index of 0.0 (95% confidence interval, 0.00–0.09). This was achieved by inhibition of ovulation, which was reflected by suppressed P levels, as the primary mode of action. Ovulation was inhibited, but otherwise ovarian activity was still present (follicle growth, E2 synthesis). The FSH serum concentrations were only slightly lower than preinsertion levels and LH surges were prevented. The viscosity of the cervical mucus was increased. The endometrium was thin but not atrophic; it showed primarily inactive or weak proliferation. Return of ovulation after removal of Implanon was rapid.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dı́az S.
        • Pavez M.
        • Moo-Young A.J.
        • Bardin C.W.
        • Croxatto H.B.
        Clinical trial with 3-ketodesogestrel subdermal implants.
        Contraception. 1991; 44: 393-408
        • Olsson S.E.
        • Odlind V.
        • Johansson E.
        Clinical results with subcutaneous implants containing 3-ketodesogestrel.
        Contraception. 1990; 42: 1-11
        • Landgren B.M.
        • Diczfalusy E.
        Hormonal effects of the 300 μg norethisterone (NET) minipill.
        Contraception. 1980; 21: 87-113
        • Mäkäräinen L.
        • van Beek A.
        • Tuomivaara L.
        • et al.
        Ovarian function during the use of a single contraceptive implant. Implanon compared with Norplant.
        Fertil Steril. 1998; 69: 714-721
        • McCann M.F.
        • Potter L.S.
        Progestin-only contraception.
        Contraception. 1994; 50: S1-S198
        • Corfman P.
        Labeling guidance text for progestin-only oral contraceptives.
        Contraception. 1995; 52: 71-76
        • Sivin I.
        International experience with Norplant® and Norplant®-2 contraceptives.
        Stud Fam Planning. 1988; 19: 81-94
        • Sivin I.
        Contraception with Norplant® implants.
        Hum Reprod. 1994; 9: 1818-1826
        • Sivin I.
        • Viegas O.
        • Campodonico I.
        • et al.
        Clinical performance of a new two-rod levonorgestrel contraceptive implant.
        Contraception. 1997; 55: 73-80
        • Affandi B.
        An integrated analysis of vaginal bleeding patterns in clinical trial of Implanon®.
        Contraception. 1998; 58: 99S-107S